During the past decade, Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" #1 sponsor was "Alkahest, Inc." with 1 trials, followed by "BioNTech SE" with 1 trials sponsored, "HUYABIO International, LLC." with 1 trials sponsored, "RHEACELL GmbH & Co. KG" with 1 trials sponsored and "University Hospital, Essen" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" #1 collaborator was "Bristol-Myers Squibb" with 1 trials as a collaborator, "FGK Clinical Research GmbH" with 1 trials as a collaborator, "Regeneron Pharmaceuticals" with 1 trials as a collaborator and "Ticeba GmbH" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" are "Malignant Melanoma Stage II" (1 trials), "Melanoma Stage III" (1 trials), "Melanoma Stage IV" (1 trials), "Pemphigoid, Bullous" (1 trials) and "Progressive Brain Metastasis" (1 trials). Many other conditions were trialed in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" in a lesser frequency.

Most popular intervention types in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" are "Drug" (4 trials) and "Biological" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "AKST4290" (1 trials), "BNT111" (1 trials), "Cemiplimab" (1 trials) and "HBI-8000 in combination with nivolumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie" are 5 trials for "All" genders.

Currently, there are NaN active trials in "Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Universitätsklinikum Freiburg Klinik für Dermatologie und Venerologie, 0 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".